Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC

Celyad Oncology SA, announced that the Company has entered into a clinical trial collaboration with MSD, a tradename of Merck & Co., Inc., through a subsidiary. Celyad Oncology will conduct the Phase Ib KEYNOTE-B79 clinical trial, which will evaluate Celyad Oncology’s investigational non-gene edited allogeneic CAR T candidate, CYAD-101, following FOLFIRI preconditioning chemotherapy, with MSD’s anti-­PD-­1 therapy, KEYTRUDA® in refractory metastatic colorectal cancer patients with microsatellite stable/ mismatch-repair proficient disease.
[Celyad Oncology]
Press Release
Bookmark

No account yet? Register

0
Share

Why Do Intestinal Epithelial Cells Express MHC Class II?

Recent studies investigating the role of MHC class II+ exosomes released by Intestinal epithelial cells report conflicting findings of either immune enhancing or immunosuppressive activities. In addition to modulating inflammatory responses, recent findings suggest that MHC class II expression by intestinal stem cells may elicit crosstalk that promotes epithelial renewal.
[Immunology]
Heuberger, C., Pott, J., & Maloy, K. J. (n.d.). Why do Intestinal Epithelial Cells Express MHC Class II? Immunology, n/a(n/a). https://doi.org/10.1111/imm.13270 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Interleukin-8 as a Candidate for Thymoma Identification and Recurrence Surveillance

Scientists identified interleukin-8 as a biomarker for auxiliary diagnosis of thymoma. They found that IL-8 levels in naïve T cells were markedly elevated in patients with thymoma compared to those with other thymic tumors.
[Nature Communications]
Gao, S., Jiang, J., Jin, C., Gao, J., Xiong, D., Yang, P., Cui, S., Yang, W., Leng, Q., Dong, J., Chen, G., Liu, J., Wang, L., Ke, A., Wang, H., & Ding, J. (2020). Interleukin-8 as a candidate for thymoma identification and recurrence surveillance. Nature Communications, 11(1), 4881. https://doi.org/10.1038/s41467-020-18697-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

SIRT1 Is Downregulated by Autophagy in Senescence and Ageing

Researchers report that macroautophagy a catabolic membrane trafficking pathway that degrades cellular components through autophagosomes and lysosomes, mediates the downregulation of mammalian SIRT1 protein during senescence and in vivo ageing.
[Nature Cell Biology]
SIRT1 is downregulated by autophagy in senescence and ageing | Nature Cell Biology. (n.d.). Retrieved September 28, 2020, from https://www.nature.com/articles/s41556-020-00579-5 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Epigenomics and Transcriptomics of Systemic Sclerosis CD4+ T Cells Reveal Long-Range Dysregulation of Key Inflammatory Pathways Mediated by Disease-Associated Susceptibility Loci

[Genome Medicine]
Epigenomics and transcriptomics of systemic sclerosis CD4+ T cells reveal long-range dysregulation of key inflammatory pathways mediated by disease-associated susceptibility loci | Genome Medicine | Full Text. (n.d.). Retrieved September 29, 2020, from https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-020-00779-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Interleukin-33 Activates Regulatory T Cells to Suppress Innate γδ T Cell Responses in the Lung

Scientists describe an unexpected function of ST2+ regulatory T cells in suppressing the innate immune response in the lung to environmental allergens without altering the adaptive immune response.
[Nature Immunology]
Faustino, L. D., Griffith, J. W., Rahimi, R. A., Nepal, K., Hamilos, D. L., Cho, J. L., Medoff, B. D., Moon, J. J., Vignali, D. A. A., & Luster, A. D. (2020). Interleukin-33 activates regulatory T cells to suppress innate γδ T cell responses in the lung. Nature Immunology, 1–13. https://doi.org/10.1038/s41590-020-0785-3 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Enhanced Safety and Anti-Tumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cell against Solid Tumor through a Synthetic Bifunctional PD-L1-Blocking Peptide

Scientists constructed a switchable dual receptor chimeric antigen receptor (CAR)-T cell whose activity was relied upon double antigens and was strictly controlled by a “switch” consisting of a PD-L1 blocking peptide conjugated to fluorescein isothiocyanate.
[Journal of the American Chemical Society]
YANG, P., Wang, Y., Yao, Z., Gao, X., Liu, C., Wang, X., Wu, H., Ding, X., Hu, J., Lin, B., Li, Q., Li, M., LI, X., Chen, X., Qi, W., Li, W., Xue, J., & Xu, H. (2020). Enhanced safety and anti-tumor efficacy of switchable dual chimeric antigen receptor-engineered T cell against solid tumor through a synthetic bifunctional PD-L1-blocking peptide. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.0c08538 Cite
Abstract
Bookmark

No account yet? Register

0
Share

SIRT1 Is Downregulated by Autophagy in Senescence and Aging

Researchers report that macroautophagy, a catabolic membrane trafficking pathway that degrades cellular components through autophagosomes and lysosomes, mediated the downregulation of mammalian SIRT1 protein during senescence and in vivo aging.
[Nature Cell Biology]
Xu, C., Wang, L., Fozouni, P., Evjen, G., Chandra, V., Jiang, J., Lu, C., Nicastri, M., Bretz, C., Winkler, J. D., Amaravadi, R., Garcia, B. A., Adams, P. D., Ott, M., Tong, W., Johansen, T., Dou, Z., & Berger, S. L. (2020). SIRT1 is downregulated by autophagy in senescence and ageing. Nature Cell Biology, 1–10. https://doi.org/10.1038/s41556-020-00579-5 Cite
Abstract
Bookmark

No account yet? Register

0
Share

BATF3 Programs CD8+ T Cell Memory

Investigators showed that BATF3 was expressed transiently within the first days after T cell priming and had long-lasting T cell–intrinsic effects.
[Nature Immunology]
Ataide, M. A., Komander, K., Knöpper, K., Peters, A. E., Wu, H., Eickhoff, S., Gogishvili, T., Weber, J., Grafen, A., Kallies, A., Garbi, N., Einsele, H., Hudecek, M., Gasteiger, G., Hölzel, M., Vaeth, M., & Kastenmüller, W. (2020). BATF3 programs CD8 + T cell memory. Nature Immunology, 1–11. https://doi.org/10.1038/s41590-020-0786-2 Cite
Abstract
Bookmark

No account yet? Register

0
Share

m6A RNA Methyltransferases METTL3/14 Regulate Immune Responses to Anti-PD-1 Therapy

Researchers showed that inhibition of N6‐methyladenosine mRNA modification by depletion of methyltransferases enhanced response to anti‐PD‐1 treatment in pMMR‐MSI‐L colorectal cancer and melanoma.
[EMBO Journal]
Wang, L., Hui, H., Agrawal, K., Kang, Y., Li, N., Tang, R., Yuan, J., & Rana, T. M. (2020). m6A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. The EMBO Journal, n/a(n/a), e104514. https://doi.org/10.15252/embj.2020104514 Cite
Full Article
Bookmark

No account yet? Register

0
Share

MAIT Cell Activation and Dynamics Associated with COVID-19 Disease Severity

Scientists investigated the MAIT cell compartment in COVID-19 patients with moderate and severe disease, as well as in convalescence. They showed profound and preferential decline in MAIT cells in the circulation of patients with active disease paired with strong activation.
[Science Immunology]
Parrot, T., Gorin, J.-B., Ponzetta, A., Maleki, K. T., Kammann, T., Emgård, J., Perez-Potti, A., Sekine, T., Rivera-Ballesteros, O., Group†, the K. C.-19 S., Gredmark-Russ, S., Rooyackers, O., Folkesson, E., Eriksson, L. I., Norrby-Teglund, A., Ljunggren, H.-G., Björkström, N. K., Aleman, S., Buggert, M., … Sandberg, J. K. (2020). MAIT cell activation and dynamics associated with COVID-19 disease severity. Science Immunology, 5(51). https://doi.org/10.1126/sciimmunol.abe1670 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share